PSNL TEM Tempus to acquire Personalis, more tightly integrating Molecular residual disease (mrd) into its AI-enabled Precision Oncology plat
PSNL TEM Tempus to acquire Personalis, more tightly integrating Molecular residual disease (mrd) into its AI-enabled Precision Oncology platform 20 Jul 2026 08:30:05 am - Personalis - deal valued at $1.50B, Personalis shareholders to receive $16.25 per share
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.